IQVIA Holdings Inc. (NYSE:IQV), a major player in clinical research services and healthcare intelligence, has announced its financial results for the first quarter of 2026, revealing robust growth across its segments and a promising outlook for the year ahead.

1. Financial Highlights

For the quarter ended March 31, 2026, IQVIA reported total revenue of $4,151 million, marking an 8.4% increase on a reported basis and a 6.0% increase at constant currency compared to the same period in 2025. The company’s performance was driven by strong demand in its Commercial Solutions and Research & Development Solutions (R&DS) segments.

Segment Performance

Commercial Solutions: Revenue surged to $1,754 million, up 11.6% on a reported basis and 8.5% at constant currency. The segment experienced notable growth in patient solutions, analytics, consulting, and commercial engagement services, particularly with the adoption of AI-enabled offerings.

Research & Development Solutions: This segment generated $2,397 million in revenue, reflecting a 6.2% increase on a reported basis and 4.2% at constant currency. Excluding reimbursed expenses, R&DS revenue grew 6.6% on a reported basis.

As of March 31, 2026, IQVIA’s R&DS contracted backlog stood at an impressive $34.2 billion, with approximately $8.9 billion expected to convert to revenue within the next twelve months.

2. Profitability Metrics

IQVIA's net income for the first quarter was $274 million, translating to a GAAP diluted earnings per share (EPS) of $1.61. On an adjusted basis, the company reported an adjusted net income of $492 million, with an adjusted diluted EPS of $2.90, reflecting a 7.4% year-over-year increase. Adjusted EBITDA also showed strength, amounting to $932 million, up 5.5% from the prior year.

Cash Flow and Debt Management

Operating cash flow reached $618 million, representing a 9% increase year over year, while free cash flow was reported at $491 million, up 15%. As of March 31, 2026, IQVIA had $1,947 million in cash and cash equivalents, with total debt of $15,833 million, resulting in a net debt position of $13,886 million. The firm’s net leverage ratio stood at 3.62x trailing twelve-month adjusted EBITDA.

3. Share Repurchase Program

During the first quarter, IQVIA executed a share repurchase program totaling $552 million. The company has $1,217 million remaining under its share repurchase authorization as of March 31, 2026.

4. Full-Year Guidance

IQVIA has reaffirmed its full-year 2026 revenue guidance, projecting revenues between $17,150 million and $17,350 million, and adjusted EBITDA between $3,975 million and $4,025 million. Notably, the company has raised its guidance for adjusted diluted EPS to between $12.65 and $12.95. This revenue forecast anticipates contributions from acquisitions and a favorable foreign exchange tailwind.

5. Leadership Commentary

Ari Bousbib, chairman and CEO of IQVIA, expressed optimism regarding the company's performance, stating, “IQVIA delivered an outstanding start to the year, with organic revenue growth accelerating more than anticipated.” He emphasized the strength in both the Commercial Solutions and R&D Solutions segments, highlighting the traction of AI-enabled offerings with customers.

6. Conclusion

IQVIA's first-quarter results showcase the company's resilience and growth potential in the evolving healthcare landscape. With a solid backlog, strong cash flow, and a clear strategy for leveraging AI and analytics, IQVIA is well-positioned to capitalize on emerging opportunities in the life sciences sector as it moves through 2026. Investors will be keen to observe how the company navigates the remainder of the year, particularly in light of its ambitious guidance and ongoing share buyback initiatives.

Original press release